跳至主要内容
临床试验/NCT07465198
NCT07465198尚未招募2 期

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

Biocells Medical1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年9月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
Change in Unified Multiple System Atrophy Rating Scale (UMSARS)

研究概览

简要总结

This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Multiple System Atrophy (MSA-P or MSA-C)
  • Age range of 35 to 65 years

排除标准

  • Other major neurological disorders
  • Severe cardiac/renal/hepatic impairment
  • Prior stem cell therapy

研究组 & 干预措施

MSC therapy

Experimental

200,000,000 cells per infusion

干预措施: MSCs (Drug)

Saline Solution

Placebo Comparator

0.9% saline infusion

干预措施: Placebo (Other)

结局指标

主要结局

Change in Unified Multiple System Atrophy Rating Scale (UMSARS)

时间窗: At week 48 from baseline

次要结局

  • Change in Health-Related Quality of Life as Measured by the 36-Item Short Form Health Survey (SF-36)(At week 48 from baseline)

研究者

发起方
Biocells Medical
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验